Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Giovambattista De Aloe is active.

Publication


Featured researches published by Giovambattista De Aloe.


Pediatric Dermatology | 2001

Rothmund-Thomson Syndrome (Thomson-Type) and Myelodysplasia

Elisa Pianigiani; Giovambattista De Aloe; Andrea Andreassi; Pietro Rubegni; Michele Fimiani

Rothmund–Thomson syndrome (RTS) is a genetic disease characterized by developmental abnormalities and poikilodermatous skin changes that appear in infancy. An association with myelodysplastic syndromes is rarely reported in RTS, even though impairment of immune function and recurrent infections are described in the literature. A case of Thomson‐type RTS in a 14‐year‐old girl with trilinear myelodysplasia is presented. The patient was kept under hematologic surveillance for myelodysplastic syndrome. Bone marrow transplantation was considered unnecessary at present.


Dermatology | 2007

Thalidomide in the Treatment of Kaposi’s Sarcoma

Pietro Rubegni; Paolo Sbano; Giovambattista De Aloe; Maria Laura Flori; Michele Fimiani

Background: Kaposi’s sarcoma (KS) is a lymphangioproliferative tumour. Therapy of KS depends on the characteristics of the disease, especially area and growth rate of lesions, and patient condition. Currently symptomatic resectable lesions are excised, whereas more advanced disease and unresectable lesions are treated with radiotherapy. If a large area or internal organs are affected or other treatments fail, chemotherapy is used. Recently some authors have reported their encouraging experience in the use of thalidomide in patients with AIDS-related KS. Objective: To evaluate the efficacy of thalidomide in 3 patients with non-AIDS-related KS. Methods: Two patients with classic widespread cutaneous and 1 with iatrogenic cutaneous and visceral KS were treated with thalidomide (100 mg/day) for 12 months. Results: In all 3 patients partial remission was evident after 4 months of thalidomide therapy; in 2 out of 3 complete remission was achieved after 12 months of treatment. Conclusions: Our results seem to confirm the utility of thalidomide in the treatment of non-AIDS-related KS.


Pediatric Dermatology | 2005

Congenital Subcutaneous Granuloma Annulare

Giovambattista De Aloe; Massimiliano Risulo; Paolo Sbano; Elisa Pianigiani; Michele Fimiani

Abstract:  Granuloma annulare is a palisading granulomatous skin disease which may be generalized, localized, perforating, or subcutaneous. Subcutaneous granuloma annulare is self‐limiting, affecting infants and children, with typical postnatal onset. Here we report a patient with congenital clinical manifestations.


Journal Der Deutschen Dermatologischen Gesellschaft | 2008

Extracorporeal photopheresis in graft-versus-host disease

Maria Rosaria Carcagnì; Giovambattista De Aloe; Giuseppina D'Ascenzo; Pietro Rubegni; Michele Fimiani

Graft‐versus‐host disease (GvHD) is a common and often serious complication of hematopoietic stem cell transplantation. There are two major forms of GvHD: an acute form which develops in the first 100days after HSCT, and a chronic form which develops later. Chronic GvHD is a multiorgan syndrome with many features of autoimmune diseases, such as sclerodermatous skin changes, cholestasis, pulmonary fibrosis, xerostomia, oral ulcerations, myositis and fasci‐itis. Unlike acute GvHD which is characterized by acute alloreactivity,the etiology of chronic GvHD is controversial and is believed to be either an extension of acute GvHD and/or a result of dysfunctional immune reconstitution with generation of autoantibodies and autoreactive T‐cell clones. GvHD is usually treated with corticosteroids and other immunosuppressants which do not always succeed in arresting its evolution. Extracorporeal photochemotherapy has been used in patients with both acute and chronic GvHD.


Human Mutation | 2001

Pseudoxanthoma elasticum: point mutations in the ABCC6 gene and a large deletion including also ABCC1 and MYH11.

Ilaria Meloni; Pietro Rubegni; Giovambattista De Aloe; Mirella Bruttini; Elisa Pianigiani; Roberto Cusano; Marco Seri; Sergio Mondillo; Antonio Federico; A. M. Bardelli; Lucio Andreassi; Michele Fimiani; Alessandra Renieri


Journal of The European Academy of Dermatology and Venereology | 1999

Primary cutaneous B-cell lymphoma: treatment with low dose intralesional recombinant interferon-alpha 2A.

Pietro Rubegni; Giovambattista De Aloe; Elisa Pianigiani; Stefano Lazzi; Michele Fimiani


Journal of The American Academy of Dermatology | 2001

Sweet's syndrome and Chlamydia pneumoniae infection

Pietro Rubegni; Maria Rosa Marano; Giovambattista De Aloe; Elisa Pianigiani; Roberta Bilenchi; Michele Fimiani


Clinics in Dermatology | 2005

Other uses of homologous skin grafts and skin bank bioproducts

Michele Fimiani; Elisa Pianigiani; Francesca Cherubini Di Simplicio; Paolo Sbano; A. Cuccia; Gerarda Pompella; Giovambattista De Aloe; Felice Petraglia


American Journal of Cardiology | 2000

Mitral valve prolapse in healthy relatives of patients with familial pseudoxanthoma elasticum

Pietro Rubegni; Sergio Mondillo; Giovambattista De Aloe; Eustachio Agricola; A. M. Bardelli; Michele Fimiani


Journal of The American Academy of Dermatology | 1999

Role of extracorporeal photochemotherapy alone and in combinationwith interferon alfa in the treatment of cutaneous T-cell lymphoma

Michele Fimiani; Pietro Rubegni; Giovambattista De Aloe; Lucio Andreassi

Collaboration


Dive into the Giovambattista De Aloe's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge